Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.

Product

Please join us for our Scientific Symposium on Sept. 10 (Auditorium 2) and at Booth 53 at the Centre de Convencions Internacional de Barcelona to learn about our new products and clinical data.

Product

Designed for super selective embolization, the mT incorporates Surefire’s new low profile and effortlessly deployed expandable tip technology for maximum dose delivery without reflux